Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 12, 2008, Pages 4289-4299

  Camargo, Ilana Lopes Baratella Da Cunha ^a,b   Neoh, Hui Min ^a,c   Cui, Longzhu ^a   Hiramatsu, Keiichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CARDIOLIPIN; DAPTOMYCIN; PHOSPHATIDYLGLYCEROL; SYNTHETASE; TEICHOIC ACID; TEICOPLANIN; VANCOMYCIN;

ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CELL WALL; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ELECTRON MICROSCOPY; GENE EXPRESSION; IN VITRO STUDY; MEMBRANE FLUIDITY; MEMBRANE POTENTIAL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROARRAY ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MPRF GENE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TAGA GENE; TAGG GENE; UPREGULATION; VRAF GENE; VRAG GENE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MEMBRANE FLUIDITY; MEMBRANE POTENTIALS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; VANCOMYCIN;

EID: 57049134826     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00417-08     Document Type: Article

References (51)

1. Allen, N. E., W. E. Alborn, Jr., and J. N. Hobbs, Jr. 1991. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob. Agents Chemother. 35:2639-2642.
2. Allen, N. E., J. N. Hobbs, and W. E. Alborn, Jr. 1987. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob. Agents Chemother. 31:1093-1099.
3. Bayer, A. S., R. Prasad, J. Chandra, A. Koul, M. Smriti, A. Varma, R. A. Skurray, N. Firth, M. H. Brown, S. P. Koo, and M. R. Yeaman. 2000. In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity. Infect. Immun. 68:3548-3553.
4. Bolhuis, H., H. W. van Veen, J. R. Brands, M. Putman, B. Poolman, A. J. Driessen, and W. N. Konings. 1996. Energetics and mechanism of drug transport mediated by the lactococcal multidrug transporter LmrP. J. Biol. Chem. 271:24123-24128.
5. Brogden, K. A. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250.
6. Reference deleted.
7. Reference deleted.
8. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. 15 December 2003, posting date. NDA 21-572, Cubicin™ (daptomycin for injection). http://www.fda.gov/cder/foi/nda/2003/21-572_Cubicin. htm. Accessed 2 October 2007.
9. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement, vol. 26, no. 3. M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Cui, L., A. Iwamoto, J. Q. Lian, H. M. Neoh, T. Maruyama, Y. Horikawa, and K. Hiramatsu. 2006. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:428-438.
11. Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.
12. Cui, L., H. Murakami, K. Kuwahara-Arai, H. Hanaki, and K. Hiramatsu. 2000. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44:2276-2285.
13. Cui, L., J. Lian, H. Neoh, R. Ethel, and K. Hiramatsu. 2005. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3404-3413.
14. Reference deleted.
15. French, G. L. 2006. Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin. J. Antimicrob. Chemother. 58:1107-1117.
16. Friedman, L., J. D. Alder, and J. A. Silverman. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145.
17. Gbaguidi, B., P. Mazurkiewicz, W. N. Konings, A. J. Driessen, J. M. Ruysschaert, and C. Vigano. 2004. Proton motive force mediates a reorientation of the cytosolic domains of the multidrug transporter LmrP. Cell. Mol. Life Sci. 61:2646-2657.
18. Hamill, O. P., and D. W. McBride, Jr. 1996. The pharmacology of mechanogated membrane ion channels. Pharmacol. Rev. 48:231-252.
19. Hayden, M. K., K. Rezai, R. A. Hayes, K. Lolans, J. P. Quinn, and R. A. Weinstein. 2005. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:5285-5287.
20. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
21. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136. (Letter.)
22. Hiramatsu, K., M. Kapi, Y. Tajima, L. Cui, S. Trakulsomboon, and T. Ito. 2005. Advances in vancomycin-resistance research in Staphylococcus aureus, p. 289-298. In D. G. White, M. N. Alekshun, P. F. McDermott, and S. B. Levy (ed.), Frontiers in antibiotic resistance: a tribute to Stuart B. Levy. ASM Press, Washington, DC.
23. Jones, T., M. R. Yeaman, G. Sakoulas, S. J. Yang, R. A. Proctor, H. G. Sahl, J. Schrenzel, Y. Q. Xiong, and A. S. Bayer. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52:269-278.
24. Jorgensen, J. H., and S. A. Crawford. 2006. Assessment of two commercial susceptibility test methods for determination of daptomycin MICs. J. Clin. Microbiol. 44:2126-2129.
25. Julian, K., K. Kosowska-Shick, C. Whitener, M. Roos, H. Labischinski, A. Rubio, L. Parent, L. Ednie, L. Koeth, T. Bogdanovich, and P. C. Appelbaum. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448.
26. Jung, D., A. Rozek, M. Okon, and R. E. Hancock. 2004. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem. Biol. 11:949-957.
27. Kaatz, G. W., T. S. Lundstrom, and S. M. Seo. 2006. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int. J. Antimicrob. Agents 28:280-287.
28. Kates, M., J. Y. Syz, D. Gosser, and T. H. Haines. 1993. pH-dissociation characteristics of cardiolipin and its 2′-deoxy analogue. Lipids 28:877-882.
29. Koo, S. P., A. S. Bayer, H. G. Sahl, R. A. Proctor, and M. R. Yeaman. 1996. Staphylocidal action of thrombin-induced platelet microbicidal protein is not solely dependent on transmembrane potential. Infect. Immun. 64:1070-1074.
30. Kuroda, M., H. Kuroda, T. Oshima, F. Takeuchi, H. Mori, and K. Hiramatsu. 2003. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol. Microbiol. 49:807-821.
31. Kuwahara-Arai, K., N. Kondo, S. Hori, E. Tateda-Suzuki, and K. Hiramatsu. 1996. Suppression of methicillin resistance in a mecA-containing pre-methicillin-resistant Staphylococcus aureus strain is caused by the mecI-mediated repression of PBP 2′ production. Antimicrob. Agents Chemother. 40:2680-2685.
32. Levina, N., S. Totemeyer, N. R. Stokes, P. Louis, M. A. Jones, and I. R. Booth. 1999. Protection of Escherichia coli cells against extreme turgor by activation of MscS and MscL mechanosensitive channels: identification of genes required for MscS activity. EMBO J. 18:1730-1737.
33. Marty, F. M., W. W. Yeh, C. B. Wennersten, L. Venkataraman, E. Albano, E. P. Alyea, H. S. Gold, L. R. Baden, and S. K. Pillai. 2006. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. 44:595-597.
34. Mascio, C. T., J. D. Alder, and J. A. Silverman. 2007. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob. Agents Chemother. 51:4255-4260.
35. Moe, P. C., G. Levin, and P. Blount. 2000. Correlating a protein structure with function of a bacterial mechanosensitive channel. J. Biol. Chem. 275:31121-31127.
36. Muthaiyan, A., J. A. Silverman, R. K. Jayaswal, and B. J. Wilkinson. 2008. Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob. Agents Chemother. 52:980-990.
37. Nagamachi, E., Y. Hirai, K. Tomochika, and Y. Kanemasa. 1992. Studies on osmotic stability of liposomes prepared with bacterial membrane lipids by carboxyfluorescein release. Microbiol. Immunol. 36:231-234.
38. 2+ channel. Microbiology 149:1147-1153.
39. Neoh, H. M., L. Cui, H. Yuzawa, F. Takeuchi, M. Matsuo, and K. Hiramatsu. 2008. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob. Agents Chemother. 52:45-53.
40. Okabe, A., Y. Hirai, H. Hayashi, and Y. Kanemasa. 1980. Alteration in phospholipid composition of Staphylococcus aureus during formation of autoplast. Biochim. Biophys. Acta 617:28-35.
41. Oku, Y., K. Kurokawa, N. Ichihashi, and K. Sekimizu. 2004. Characterization of the Staphylococcus aureus mprF gene, involved in lysinylation of phosphatidylglycerol. Microbiology 150:45-51.
42. Reference deleted.
43. Pillai, S. K., H. S. Gold, G. Sakoulas, C. Wennersten, R. C. Moellering, Jr., and G. M. Eliopoulos. 2007. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob. Agents Chemother. 51:2223-2225.
44. Reference deleted.
45. Reference deleted.
46. Reference deleted.
47. Silverman, J. A., N. Oliver, T. Andrew, and T. Li. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802.
48. Silverman, J. A., N. G. Perlmutter, and H. M. Shapiro. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544.
49. Straus, S. K., and R. E. Hancock. 2006. Mode of action of the new antibiotic for gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758:1215-1223.
50. Vikram, H. R., N. L. Havill, L. M. Koeth, and J. M. Boyce. 2005. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J. Clin. Microbiol. 43:5384-5387.
51. Xiong, Y. Q., K. Mukhopadhyay, M. R. Yeaman, J. Adler-Moore, and A. S. Bayer. 2005. Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3114-3121.